Related references
Note: Only part of the references are listed.PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model
Ming Du et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Eukaryotic ribosomal RNA determinants of aminoglycoside resistance and their role in translational fidelity
Hua Fan-Minogue et al.
RNA (2008)
No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations
John P. Clancy et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2007)
Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model
Ming Du et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2006)
Readthrough of dystrophin stop codon mutations induced by aminoglycosides
MT Howard et al.
ANNALS OF NEUROLOGY (2004)
Pharmacologic therapy for stop mutations: how much CFTR activity is enough?
E Kerem
CURRENT OPINION IN PULMONARY MEDICINE (2004)
Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations
M Wilschanski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Aminoglycoside suppression of a premature stop mutation in a Cftr-/- mouse carrying a human CFTR-G542X transgene
M Du et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2002)
Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system
KM Keeling et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2002)
Megalin deficiency offers protection from renal aminoglycoside accumulation
C Schmitz et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis
JP Clancy et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2001)
Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of α-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation
KM Keeling et al.
HUMAN MOLECULAR GENETICS (2001)
A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations
M Wilschanski et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2000)
Share Paper
